Loading...
Market
GSK COVID-19 Vaccine Phase 3 Trials Start by Mid-2024?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
GSK press releases or clinical trial databases
Story
GSK Secures Full Rights to Develop COVID-19 and Influenza Vaccines from CureVac
Jul 3, 2024, 06:30 AM
GlaxoSmithKline (GSK) has announced a new licensing agreement with CureVac, securing full rights to develop and manufacture COVID-19 and influenza vaccines. This strategic investment in vaccine platform technologies aims to enhance GSK's ability to match the best platform to each pathogen, ultimately helping to prevent illness in more people worldwide.
View original story
Similar markets
Positive • 33%
Neutral • 33%
Negative • 33%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial discontinued • 25%
